Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; t… Read more
Smith & Nephew plc (SNNUF) - Net Assets
Latest net assets as of June 2025: $5.54 Billion USD
Based on the latest financial reports, Smith & Nephew plc (SNNUF) has net assets worth $5.54 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.69 Billion) and total liabilities ($5.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.54 Billion |
| % of Total Assets | 51.78% |
| Annual Growth Rate | 7.88% |
| 5-Year Change | -0.27% |
| 10-Year Change | 32.75% |
| Growth Volatility | 19.95 |
Smith & Nephew plc - Net Assets Trend (1985–2024)
This chart illustrates how Smith & Nephew plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Smith & Nephew plc (1985–2024)
The table below shows the annual net assets of Smith & Nephew plc from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.26 Billion | +0.92% |
| 2023-12-31 | $5.22 Billion | -0.80% |
| 2022-12-31 | $5.26 Billion | -5.55% |
| 2021-12-31 | $5.57 Billion | +5.47% |
| 2020-12-31 | $5.28 Billion | +2.68% |
| 2019-12-31 | $5.14 Billion | +5.48% |
| 2018-12-31 | $4.87 Billion | +4.95% |
| 2017-12-31 | $4.64 Billion | +17.33% |
| 2016-12-31 | $3.96 Billion | -0.20% |
| 2015-12-31 | $3.97 Billion | -1.83% |
| 2014-12-31 | $4.04 Billion | -0.17% |
| 2013-12-31 | $4.05 Billion | +4.20% |
| 2012-12-31 | $3.88 Billion | +21.87% |
| 2011-12-31 | $3.19 Billion | +14.93% |
| 2010-12-31 | $2.77 Billion | +27.26% |
| 2009-12-31 | $2.18 Billion | +28.25% |
| 2008-12-31 | $1.70 Billion | -6.44% |
| 2007-12-31 | $1.82 Billion | -16.47% |
| 2006-12-31 | $2.17 Billion | +51.50% |
| 2005-12-31 | $1.44 Billion | +6.57% |
| 2004-12-31 | $1.35 Billion | +17.67% |
| 2003-12-31 | $1.14 Billion | +37.33% |
| 2002-12-31 | $833.21 Million | +41.42% |
| 2001-12-31 | $589.18 Million | +47.35% |
| 2000-12-31 | $399.84 Million | -55.20% |
| 1999-12-31 | $892.49 Million | +10.75% |
| 1998-12-31 | $805.88 Million | +5.68% |
| 1997-12-31 | $762.58 Million | +2.27% |
| 1996-12-31 | $745.62 Million | +19.23% |
| 1995-12-31 | $625.35 Million | -10.30% |
| 1994-12-31 | $697.12 Million | +35.58% |
| 1993-12-31 | $514.17 Million | -6.40% |
| 1992-12-31 | $549.35 Million | +1.97% |
| 1991-12-31 | $538.71 Million | +3.40% |
| 1990-12-31 | $521.01 Million | +29.67% |
| 1989-12-31 | $401.80 Million | -7.36% |
| 1988-12-31 | $433.72 Million | -2.82% |
| 1987-12-31 | $446.29 Million | +43.34% |
| 1986-12-31 | $311.35 Million | +13.80% |
| 1985-12-31 | $273.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Smith & Nephew plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4292.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $5.02 Billion | 95.31% |
| Common Stock | $175.00 Million | 3.32% |
| Other Comprehensive Income | $-477.00 Million | -9.06% |
| Other Components | $549.00 Million | 10.43% |
| Total Equity | $5.26 Billion | 100.00% |
Smith & Nephew plc Competitors by Market Cap
The table below lists competitors of Smith & Nephew plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Verona Pharma plc
F:I9SA
|
$12.46 Billion |
|
WESCO International Inc
NYSE:WCC
|
$12.48 Billion |
|
Roku Inc
NASDAQ:ROKU
|
$12.48 Billion |
|
A.P. Møller - Mærsk A/S
PINK:AMKBF
|
$12.49 Billion |
|
TCEYF
PINK:TCEYF
|
$12.44 Billion |
|
Allegion PLC
NYSE:ALLE
|
$12.39 Billion |
|
Inpex Corporation
PINK:IPXHF
|
$12.38 Billion |
|
Neste Oil Oyj
HE:NESTE
|
$12.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Smith & Nephew plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,217,000,000 to 5,265,000,000, a change of 48,000,000 (0.9%).
- Net income of 412,000,000 contributed positively to equity growth.
- Dividend payments of 327,000,000 reduced retained earnings.
- New share issuances of 1,000,000 increased equity.
- Other comprehensive income decreased equity by 92,543,615.
- Other factors increased equity by 54,543,615.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $412.00 Million | +7.83% |
| Dividends Paid | $327.00 Million | -6.21% |
| Share Issuances | $1.00 Million | +0.02% |
| Other Comprehensive Income | $-92.54 Million | -1.76% |
| Other Changes | $54.54 Million | +1.04% |
| Total Change | $- | 0.92% |
Book Value vs Market Value Analysis
This analysis compares Smith & Nephew plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 35.03x to 2.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.41 | $14.33 | x |
| 1986-12-31 | $0.28 | $14.33 | x |
| 1987-12-31 | $0.29 | $14.33 | x |
| 1988-12-31 | $0.27 | $14.33 | x |
| 1989-12-31 | $0.17 | $14.33 | x |
| 1990-12-31 | $0.23 | $14.33 | x |
| 1991-12-31 | $0.24 | $14.33 | x |
| 1992-12-31 | $0.26 | $14.33 | x |
| 1993-12-31 | $0.30 | $14.33 | x |
| 1994-12-31 | $0.39 | $14.33 | x |
| 1995-12-31 | $0.35 | $14.33 | x |
| 1996-12-31 | $0.41 | $14.33 | x |
| 1997-12-31 | $0.42 | $14.33 | x |
| 1998-12-31 | $0.44 | $14.33 | x |
| 1999-12-31 | $0.55 | $14.33 | x |
| 2000-12-31 | $0.19 | $14.33 | x |
| 2001-12-31 | $0.32 | $14.33 | x |
| 2002-12-31 | $0.44 | $14.33 | x |
| 2003-12-31 | $1.22 | $14.33 | x |
| 2004-12-31 | $1.43 | $14.33 | x |
| 2005-12-31 | $1.52 | $14.33 | x |
| 2006-12-31 | $2.30 | $14.33 | x |
| 2007-12-31 | $1.96 | $14.33 | x |
| 2008-12-31 | $1.91 | $14.33 | x |
| 2009-12-31 | $1.23 | $14.33 | x |
| 2010-12-31 | $1.56 | $14.33 | x |
| 2011-12-31 | $1.78 | $14.33 | x |
| 2012-12-31 | $4.31 | $14.33 | x |
| 2013-12-31 | $4.47 | $14.33 | x |
| 2014-12-31 | $4.49 | $14.33 | x |
| 2015-12-31 | $4.42 | $14.33 | x |
| 2016-12-31 | $4.43 | $14.33 | x |
| 2017-12-31 | $5.31 | $14.33 | x |
| 2018-12-31 | $5.57 | $14.33 | x |
| 2019-12-31 | $5.86 | $14.33 | x |
| 2020-12-31 | $6.02 | $14.33 | x |
| 2021-12-31 | $6.34 | $14.33 | x |
| 2022-12-31 | $6.02 | $14.33 | x |
| 2023-12-31 | $5.98 | $14.33 | x |
| 2024-12-31 | $6.01 | $14.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Smith & Nephew plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.83%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.09%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.97x
- Recent ROE (7.83%) is below the historical average (22.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 25.05% | 11.23% | 0.95x | 2.36x | $41.12 Million |
| 1986 | 28.72% | 12.58% | 0.80x | 2.86x | $58.20 Million |
| 1987 | 31.53% | 13.73% | 0.83x | 2.75x | $95.95 Million |
| 1988 | 33.53% | 13.48% | 0.85x | 2.94x | $101.92 Million |
| 1989 | 54.09% | 12.96% | 0.84x | 4.96x | $120.33 Million |
| 1990 | 39.09% | 10.17% | 0.92x | 4.19x | $106.52 Million |
| 1991 | 19.22% | 5.04% | 0.94x | 4.07x | $35.81 Million |
| 1992 | 36.47% | 11.99% | 0.97x | 3.14x | $113.16 Million |
| 1993 | 31.30% | 11.46% | 1.07x | 2.54x | $109.42 Million |
| 1994 | -12.10% | -5.59% | 1.14x | 1.90x | $-153.93 Million |
| 1995 | 27.89% | 10.99% | 1.25x | 2.04x | $111.81 Million |
| 1996 | 27.74% | 11.29% | 1.27x | 1.93x | $132.19 Million |
| 1997 | 24.66% | 10.85% | 1.21x | 1.87x | $111.75 Million |
| 1998 | 19.31% | 8.90% | 1.16x | 1.87x | $74.99 Million |
| 1999 | 19.01% | 9.36% | 1.14x | 1.78x | $80.34 Million |
| 2000 | 77.51% | 18.29% | 1.18x | 3.60x | $269.94 Million |
| 2001 | 32.03% | 11.98% | 0.99x | 2.71x | $129.81 Million |
| 2002 | 22.17% | 10.33% | 0.90x | 2.39x | $101.43 Million |
| 2003 | 23.11% | 12.56% | 0.95x | 1.94x | $150.04 Million |
| 2004 | 21.54% | 12.11% | 0.82x | 2.17x | $155.36 Million |
| 2005 | 23.21% | 13.05% | 0.86x | 2.07x | $189.50 Million |
| 2006 | 34.27% | 26.81% | 0.86x | 1.49x | $527.60 Million |
| 2007 | 17.40% | 9.38% | 0.76x | 2.46x | $134.40 Million |
| 2008 | 22.19% | 9.92% | 0.84x | 2.65x | $207.10 Million |
| 2009 | 21.66% | 12.51% | 0.83x | 2.09x | $254.10 Million |
| 2010 | 22.18% | 15.52% | 0.84x | 1.71x | $337.70 Million |
| 2011 | 18.26% | 13.63% | 0.90x | 1.49x | $263.30 Million |
| 2012 | 18.77% | 17.62% | 0.73x | 1.45x | $340.60 Million |
| 2013 | 13.74% | 12.78% | 0.75x | 1.44x | $151.30 Million |
| 2014 | 12.40% | 10.85% | 0.63x | 1.81x | $97.00 Million |
| 2015 | 10.34% | 8.85% | 0.65x | 1.81x | $13.40 Million |
| 2016 | 19.81% | 16.79% | 0.64x | 1.86x | $388.20 Million |
| 2017 | 16.52% | 16.10% | 0.61x | 1.69x | $302.60 Million |
| 2018 | 13.60% | 13.52% | 0.61x | 1.65x | $175.60 Million |
| 2019 | 11.67% | 11.68% | 0.55x | 1.81x | $85.90 Million |
| 2020 | 8.49% | 9.82% | 0.41x | 2.09x | $-79.90 Million |
| 2021 | 9.41% | 10.05% | 0.48x | 1.96x | $-32.80 Million |
| 2022 | 4.24% | 4.28% | 0.52x | 1.90x | $-302.90 Million |
| 2023 | 5.04% | 4.74% | 0.56x | 1.91x | $-258.70 Million |
| 2024 | 7.83% | 7.09% | 0.56x | 1.97x | $-114.50 Million |
Industry Comparison
This section compares Smith & Nephew plc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Smith & Nephew plc (SNNUF) | $5.54 Billion | 25.05% | 0.93x | $12.44 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |